SG11201809725TA - Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist - Google Patents
Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonistInfo
- Publication number
- SG11201809725TA SG11201809725TA SG11201809725TA SG11201809725TA SG11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- serene
- avenue
- international
- banjara
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 239000004783 Serene Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/199072 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- A61K 31/13 (2006.01) A61P 25/28 (2006.01) derabad, Telangana 500034 (IN). A61K 31/496 (2006.01) (74) Agent: BHASIN, Gayatri et al.; Central Square, Suite - (21) International Application Number: 328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu PCT/IB2016/054674 Rao (off Rani Jhansi Road), Delhi 110 006 (IN). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 03 August 2016 (03.08.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, (30) Priority Data: LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, 201641017203 18 May 2016 (18.05.2016) IN MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, (71) Applicant: SUVEN LIFE SCIENCES LIMITED PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, [IN/IN]; Serene Chambers, Road-5, Avenue — 7, Banjara SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, Hills, Hyderabad, Telangana 500034 (IN). UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: NIROGI, Ramakrishna; Serene Chambers, (84) Designated States (unless otherwise indicated, for every Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telangana kind of regional protection available): ARIPO (BW, GH, _ 500034 (IN). SHINDE, Anil Karbhari; Serene Cham- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, gana 500034 (IN). JAYARAJAN, Pradeep; Serene Cham- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = gana 500034 (IN). BHYRAPUNENI, Gopinadh; Serene MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, _ Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Telangana 500034 (IN). KAMBHAMPATI, Ramasastri; KM, ML, MR, NE, SN, TD, TG). Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- _ derabad, Telangana 500034 (IN). JASTI, Venkateswarlu; = = (54) Title: COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST = = — Figure la = = 0.8- a) -cs c 0.7- ._ a) - = = = > = 2 0.6- = ._ — E '= c.) 0.5- co in _ = 0.4 — Vehicle Compound 1 Vehicle Compound 1 Il 2 m L/kg, p.o. 1 mg/kg, p.o. 2 mL/kg, p.o. 1 mg/kg, p.o. Vehicle Vehicle Memantine, Memantine, el IN 2 m L/kg, p.o. 2 mL/kg, p.o. 0.3 mg/kg, p.o. 0.3 mg/kg, p.o. © Dala represents Mean ± SEM of discriminative index. *p<0.05 Vs vehicle (Kruskal-Wallis 0\ 0\ followed by Dunn's Multiple Comparison Tesl) N=8-11 1-1 IN 1-1 (57) : The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in C:::: ) combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further el relates to the pharmaceutical composition containing the said combination. [Continued on next page] WO 2017/199072 Al MIDEDIMOMMIDIRMEMMICHIMONMOIIIMEMOE# Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641017203 | 2016-05-18 | ||
PCT/IB2016/054674 WO2017199072A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809725TA true SG11201809725TA (en) | 2018-12-28 |
Family
ID=56940099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809725TA SG11201809725TA (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Country Status (19)
Country | Link |
---|---|
US (1) | US11116764B2 (en) |
EP (1) | EP3458040B1 (en) |
JP (1) | JP6606298B2 (en) |
KR (1) | KR102023748B1 (en) |
CN (1) | CN109069449A (en) |
AU (1) | AU2016407428B2 (en) |
BR (1) | BR112018073396A2 (en) |
CA (1) | CA3023828C (en) |
DK (1) | DK3458040T3 (en) |
EA (1) | EA036301B1 (en) |
HK (1) | HK1258023A1 (en) |
HR (1) | HRP20210640T1 (en) |
HU (1) | HUE055083T2 (en) |
IL (1) | IL262816B (en) |
MX (1) | MX2018013969A (en) |
NZ (1) | NZ747778A (en) |
SG (1) | SG11201809725TA (en) |
WO (1) | WO2017199072A1 (en) |
ZA (1) | ZA201807311B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102508303B1 (en) * | 2017-07-03 | 2023-03-09 | 수벤 라이프 사이언시스 리미티드 | Novel uses of pure 5-HT6 receptor antagonists |
MX2022006535A (en) * | 2019-12-02 | 2022-09-09 | Suven Life Sciences Ltd | Treating behavioral and psychological symptoms in dementia patients. |
CN114761008B (en) * | 2019-12-02 | 2024-07-19 | 苏文生命科学有限公司 | Method for treating behavioral and psychological symptoms in patients suffering from dementia |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1581492T1 (en) * | 2002-11-28 | 2008-12-31 | Suven Life Sciences Ltd | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
BR112016010788B1 (en) | 2013-12-02 | 2023-03-21 | Suven Life Sciences Limited | PROCESS FOR THE LARGE-SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE |
-
2016
- 2016-08-03 SG SG11201809725TA patent/SG11201809725TA/en unknown
- 2016-08-03 NZ NZ747778A patent/NZ747778A/en unknown
- 2016-08-03 US US16/097,458 patent/US11116764B2/en active Active
- 2016-08-03 CN CN201680085559.6A patent/CN109069449A/en active Pending
- 2016-08-03 JP JP2018559283A patent/JP6606298B2/en active Active
- 2016-08-03 BR BR112018073396-2A patent/BR112018073396A2/en not_active Application Discontinuation
- 2016-08-03 EA EA201892583A patent/EA036301B1/en unknown
- 2016-08-03 KR KR1020187035901A patent/KR102023748B1/en active IP Right Grant
- 2016-08-03 AU AU2016407428A patent/AU2016407428B2/en active Active
- 2016-08-03 WO PCT/IB2016/054674 patent/WO2017199072A1/en active Search and Examination
- 2016-08-03 MX MX2018013969A patent/MX2018013969A/en unknown
- 2016-08-03 EP EP16766623.9A patent/EP3458040B1/en active Active
- 2016-08-03 HU HUE16766623A patent/HUE055083T2/en unknown
- 2016-08-03 DK DK16766623.9T patent/DK3458040T3/en active
- 2016-08-03 CA CA3023828A patent/CA3023828C/en active Active
-
2018
- 2018-10-31 ZA ZA2018/07311A patent/ZA201807311B/en unknown
- 2018-11-06 IL IL262816A patent/IL262816B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100394.1A patent/HK1258023A1/en unknown
-
2021
- 2021-04-22 HR HRP20210640TT patent/HRP20210640T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3458040B1 (en) | 2021-01-27 |
KR102023748B1 (en) | 2019-09-20 |
IL262816A (en) | 2018-12-31 |
IL262816B (en) | 2020-05-31 |
BR112018073396A2 (en) | 2019-03-19 |
NZ747778A (en) | 2020-03-27 |
DK3458040T3 (en) | 2021-05-03 |
HUE055083T2 (en) | 2021-10-28 |
HRP20210640T1 (en) | 2021-06-25 |
JP6606298B2 (en) | 2019-11-13 |
US11116764B2 (en) | 2021-09-14 |
EA201892583A1 (en) | 2019-04-30 |
CN109069449A (en) | 2018-12-21 |
ZA201807311B (en) | 2020-01-29 |
AU2016407428A1 (en) | 2018-11-29 |
WO2017199072A1 (en) | 2017-11-23 |
CA3023828C (en) | 2019-08-27 |
AU2016407428B2 (en) | 2019-11-21 |
EP3458040A1 (en) | 2019-03-27 |
HK1258023A1 (en) | 2019-11-01 |
US20190175586A1 (en) | 2019-06-13 |
CA3023828A1 (en) | 2017-11-23 |
MX2018013969A (en) | 2019-03-21 |
EA036301B1 (en) | 2020-10-23 |
KR20180136566A (en) | 2018-12-24 |
JP2019516696A (en) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201408140QA (en) | Crystalline forms of an androgen receptor modulator | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201407988UA (en) | Process for improved opioid synthesis | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201910043PA (en) | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |